Search results
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Forrest City Times-Herald· 2 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...
Quadruplet Regimens Have Become Standard for Multiple Myeloma
MedPage Today· 6 days agoWhile triplet regimens were once standard for newly diagnosed multiple myeloma, more recent studies...
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both...
Valley City Times Record· 2 days agoJohnson & Johnson today announced data from the Phase 3 PERSEUS study showing deepening of responses...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 2 days agoLongeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. The company today announced the launch of its contract development and
